#United States #San Diego #Deck Bio #DBXO-1 #T Cell Engager

Deck Bio Unveils Preclinical Breakthroughs on DBXO-1 at AACR 2026

In the bustling city of San Diego, California, from April 17 to 22, 2026, the American Association for Cancer Research (AACR) Annual Meeting served as a platform for a transformative presentation by Deck Bio. The biotechnology firm is pioneering innovative treatments that harness the power of multi-pMHC targeted T cell engagers aimed at combating solid tumors. Their lead candidate, DBXO-1, was the focal point of the presentation, showcasing promising preclinical data that could revolutionize the approach to cancer therapy.

Addressing Fundamental Challenges in Cancer Treatment

The landscape of cancer treatment is fraught with challenges, particularly in the realm of solid tumors, which often exhibit low antigen density, significant heterogeneity, and a scarcity of surface antigens specific to tumors. Deck Bio's innovative solution proposes to overcome these obstacles with DBXO-1, engineered to recognize various cancer-associated peptide-major histocompatibility complexes (pMHCs) using a single engineered T cell receptor (TCR)-based binder.

Dr. Johanna Kaufmann, the Chief Scientific Officer of Deck Bio, articulated the significance of this approach: "The data we presented exhibit not just the rationale but the structural foundation necessary for effective multi-pMHC targeting. We focus on specificity as a fundamental design principle, ensuring that the enhanced multi-target capability does not compromise on off-target toxicity."

Key Findings from the AACR Presentation

The data presented at the AACR meeting elaborated on several critical findings:

1. Multi-Target Engagement: Engineered TCR-based binders showcased remarkable multi-target engagement, with affinities around 1–2 nM across the pMHC targets.
2. Structural Recognition: The structural recognition mechanism of the DBXO-1 binders emphasized its potential to effectively target multiple pMHC complexes.
3. Specificity Profiling: Advanced assessments using Deck Bio's proprietary dbSCOPE technology interrogated binding against over 13,849 healthy tissue-presented peptides, revealing minimal off-target interactions. The resulting specificity profile was akin to that of existing approved pMHC-TCEs.
4. Potency and Efficacy: Functional assays conducted under stringent conditions demonstrated that DBXO-1 maintained a favorable potency window, evidenced by over a 1,000-fold EC50 selectivity for target versus off-target peptides and facilitated effective T cell activation and target-dependent cytotoxicity comparable to established T cell engagers.
5. Stability and Longevity: The DBXO-1 formulation exhibited extended half-life properties in human FcRn transgenic mice, with estimations indicating a half-life exceeding 7.5 days.

Future Directions and Potential Impact

Dr. Jack Silberstein, the Founder and CEO of Deck Bio, asserted, "These results validate our belief in a multi-target strategy as a means to broaden the efficacy of T cell engagers against solid tumors while maintaining high specificity standards." With ongoing preclinical investigations exploring further safety and efficacy, DBXO-1 aims to advance through to clinical trials. Initial phases will focus on biomarker-selected patient populations, particularly those battling non-small cell lung and gastroesophageal cancers, an estimated 120,000 biomarker-positive patients who might benefit from this breakthrough therapy.

Deck Bio stands at the forefront of transforming cancer therapy, their commitment underscored by a drive to enhance patient outcomes through innovative immunotherapies. Headquartered in Cambridge, Massachusetts, the firm integrates various proprietary technologies—including dbTv™, a TCR stabilization technology, dbTCE™, a novel T cell engager format, and dbSCOPE™, a peptidome-wide specificity profiling platform—into their development processes. Each aspect aims to improve safety and efficacy while addressing unmet patient needs in oncological treatments.

For more information on their cutting-edge work, visit deck.bio and follow their journey on LinkedIn.